<sub id="h9hdp"></sub>
      <span id="h9hdp"></span>
        <sub id="h9hdp"></sub>
        <sub id="h9hdp"></sub>

        <address id="h9hdp"></address>

          <thead id="h9hdp"></thead>

            Could COVID-19 be a catalyst for virtualizing clinical trials?

            The virtualization of clinical trials has long been technically feasible, but cultural and regulatory barriers have prevented implementation. With over 1200 clinical trials worldwide being...
            Learn More

            Adapting to Our “New” Virtual Reality in Biotech

            In the current crisis, working virtually is now a reality for many. The preparedness for this varies greatly. For some it’s business as usual, for others “going virtual” simply hasn’t been feasible,...
            Learn More

            Pipeline asset valuation: garbage in – garbage out

            Methods of valuing pharmaceutical development-stage assets have been a perennial talking point for decades, and the advantages and disadvantages of each have been covered in numerous publications....
            Learn More

            COVID-19: a catalyst for anti-infective investing?

            There has been a persistent call from early stage innovators to shine a spotlight on building anti-infective defenses in light of the looming crisis of antimicrobial resistance (AMR). Unfortunately,...
            Learn More

            The risk-reward balance in drug repurposing

            Does drug repurposing overcome the hurdles and pitfalls in drug development? Having conducted several recent due diligence exercises in the repurposing space, we discuss the gems and the hidden...
            Learn More

            Gene Therapy: Suspending Vector Immunity and Facilitating Re-Dosing?

            Vector immunity is currently a major limiting factor in gene therapy. In the first place, patients with pre-existing immunity may either be ineligible for treatment or may require extremely high...
            Learn More

            Pharmaceutical Patents: an overview

            Protecting new treatments and innovations is critical for the drug developers. In this article and its presentation, we provide of an overview of the history of patents, what a patent is, the general...
            Learn More

            Moving beyond cancer: CAR-T therapy takes on autoimmune disease

            It’s not untypical for an emerging cancer treatments to be dubbed “revolutionary” or “game-changing”, but stepping beyond cliché, chimeric antigen receptor T-cell (“CAR-T”) therapy can rightly be...
            Learn More

            Monetizing the microbiome

            Based on some neat guesstimating1, the number of bacteria in the gut roughly equals the number of cells in our bodies, so it’s no surprise that such a substantial (around 200g in a 70kg adult) and...
            Learn More

            Pharma Valuations: When to Use Incidence and/or Prevalence

            Many would agree that input assumptions are the most important part of a pharma or biotech portfolio valuation. Of these, one particularly critical assumption is the addressable patient population,...
            Learn More

            Summer in Paris: NASH Update

            Title: Summer in Paris: NASH Update Author: Peter G. Traber, MD Date: 07/16/2019 The Paris NASH meeting was held July 11 and 12, 2019, subtitled as an “International Think Tank” and it certainly did...
            Learn More

            No Acceptable Surrogates for NASH Cirrhosis

            Title: No Acceptable Surrogates for NASH Cirrhosis Author: Peter G. Traber, MD Date: 06/06/2019 The FDA released draft guidance on developing drugs for compensated NASH cirrhosis (Nonalcoholic...
            Learn More
            1 2 3 4
            中文无码人妻影音先锋